Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori

Next Previous
X
Search
Trial Profile

Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nitazoxanide (Primary) ; Clarithromycin; Doxycycline; Levofloxacin; Metronidazole; Omeprazole
  • Indications Helicobacter pylori infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 04 Apr 2019 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified April 2017).
    • 06 Dec 2017 Status changed to active, no longer recruiting.
    • 01 Nov 2017 Results assessing the efficacy and safety of a unique triple Nitazoxanide containing regimen presented at the 25th United European Gastroenterology Week

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top